BSTG News and Press, Biostage From 08/04/22

Biostage Reports Corporate Highlights and Second Quarter Financial Results PR Newswire HOLLISTON, Mass. , Aug. 4, 2022 /PRNewswire/ --Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful fir...

Biostage Schedules Conference Call and Webcast for Q2 2022 Results PR Newswire HOLLISTON, Mass. , Aug. 4, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-h...

The IPO market’s short week ended up being quieter than expected. Just one small IPO and one SPAC began trading, while the only major deal on the calendar delayed its pricing. China-based Golden Sun Education priced at the low end to raise $18 million at a $70 million market ca...

Biostage has filed to raise capital via an uplisting IPO to Nasdaq. The firm is developing treatments for the various gastrointestinal system and airway conditions. BSTG is still at the preclinical stage of development, so the IPO is ultra-high-risk. For further details see:...

A cell-therapy biotechnology company, Biostage Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), has announced today the publication of a paper in the peer-reviewed Journal of Biomechanics. This published paper describes a study investigat...

Biostage Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of Biomechanics PR Newswire The current study tested the biomechanical strength of the newly regenerated esophageal tissue and demonstrated that the strength of the ...

Biostage, Inc. (BSTG) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Peter Pellegrino - Interim Vice President of Finance David Green - Interim Chief Executive Officer Presentation Operator Greetings. Welcome to the Biostage Q1 2022 Conference Call. At this time...

Biostage Reports Q1 2022 Financial Results and Corporate Highlights PR Newswire HOLLISTON, Mass. , May 16, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-...

Cell-therapy biotechnology company, Biostage (OTC:BSTG) raises ~$5.1M from new and existing investors in a private placement of its shares.  The funds will be used to accelerate the clinical development of Biostage's lead product candidate, the Biostage Esophageal Implant, or BEI. C...

Biostage Announces $5.1 Million Financing to Advance Clinical Trial PR Newswire HOLLISTON , Mass. , May 13, 2022 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-...